DC
ENTA icon

Deere & Company’s Enanta Pharmaceuticals ENTA Stock Holding History

Deere & Company’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-29,392
Closed -$782K – 237
2016
Q3 		$782K Buy
+29,392
New +$683K 0.04% 472
2013
Q4 		– Sell
-28,502
Closed -$653K – 1001
2013
Q3 		$653K Buy
+28,502
New +$545K 0.04% 525

Other funds holding ENTA

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Deere & Company's ENTA Position: Q4 2016 in Review

Deere & Company sold out of Enanta Pharmaceuticals (ENTA) in Q4 2016, closing a stake of 29,392 shares — an estimated $782K sold.

Deere & Company first reported a position in ENTA in Q3 2013 and held it in 2 quarters. The position peaked at $782K in Q3 2016. 149 funds tracked by Wall St. Rank hold ENTA as of Q4 2016.

  • Deere & Company reported no remaining Enanta Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Deere & Company sold 29,392 Enanta Pharmaceuticals shares in Q4 2016, an estimated $782K.
  • Deere & Company first reported a position in Enanta Pharmaceuticals in Q3 2013 and held it in 2 quarters.
  • Deere & Company's Enanta Pharmaceuticals position peaked at $782K in Q3 2016.
  • 149 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2016.

Based on Deere & Company's 13F filing for Q4 2016, filed 13 Feb 2017.